Venclose Revenue and Competitors
Estimated Revenue & Valuation
- Venclose's estimated annual revenue is currently $5M per year.
- Venclose's estimated revenue per employee is $125,500
- Venclose's total funding is $27M.
Employee Data
- Venclose has 40 Employees.
- Venclose grew their employee count by -18% last year.
Venclose's People
Name | Title | Email/Phone |
---|---|---|
1 | Area VP Sales | Reveal Email/Phone |
2 | CFO | Reveal Email/Phone |
3 | COO | Reveal Email/Phone |
4 | VP Research & Development | Reveal Email/Phone |
5 | SVP, Global Sales & Marketing | Reveal Email/Phone |
6 | VP, Sales Europe/Middle East | Reveal Email/Phone |
7 | VP Sales and Marketing Europe | Reveal Email/Phone |
8 | Senior Director Regulatory and Clinical Affairs | Reveal Email/Phone |
9 | Director R&D, Product Development | Reveal Email/Phone |
10 | Chief Medical Officer | Reveal Email/Phone |
Venclose Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $20.3M | 81 | 7% | N/A | N/A |
#2 | $8.5M | 34 | 6% | N/A | N/A |
#3 | $4.5M | 18 | -10% | N/A | N/A |
#4 | $8M | 32 | -6% | N/A | N/A |
#5 | $5.3M | 21 | 0% | N/A | N/A |
#6 | $54.2M | 216 | 9% | N/A | N/A |
#7 | $12M | 48 | N/A | N/A | N/A |
#8 | $10M | 40 | 5% | N/A | N/A |
#9 | $30.1M | 120 | 22% | N/A | N/A |
#10 | $14.1M | 56 | 2% | N/A | N/A |
What Is Venclose?
We are a medical technology company developing next-generation solutions for the treatment of chronic venous insufficiency, a progressive medical condition affecting an estimated 10% of adults. Our Mission To improve the physician and patient experience during chronic venous insufficiency treatment by commercializing the next-generation RF therapy.
keywords:N/A$27M
Total Funding
40
Number of Employees
$5M
Revenue (est)
-18%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Venclose News
SAN JOSE, Calif., Nov. 30, 2020 /PRNewswire/ -- Venclose Inc., a privately-held medical device corporation focused on innovative advancements for the minimally invasive treatment of chronic venous insufficiency, a major underlying cause of varicose veins, today announced that Jerry Gibson, Ven ...
SAN JOSE, Calif., Dec. 3, 2019 /PRNewswire/ — Venclose, Inc., a privately-held Silicon Valley medical device company focused on innovative treatment procedures for venous reflux disease, today announced it has closed its Series C funding led by Ally Bridge Group (ABG). ABG is a global life scien ...
Venous reflux disease treatment developer Venclose announced that it closed a Series C funding round totaling $27 million. Venclose develops the next-generation Venclose RF ablation system designed to close damaged veins and restore healthy blood flow in patients with venous reflux disease. Th ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $8.6M | 40 | -9% | N/A |
#2 | $4.6M | 40 | -44% | N/A |
#3 | $4.4M | 40 | 33% | $13M |
#4 | $11.2M | 40 | -9% | N/A |
#5 | $7.8M | 40 | -5% | N/A |